Setting new standards in information exchange for the pharmaceutical and biotech industry

Overview

Since 2012, the Government Pricing industry primarily focused its energy on Medicaid as they awaited the AMP Final Rule. The changes with the 340B program and shift in payer mix to MMCOs caused operational challenges, increased financial, compliance and contractual burdens. With the increase in complexity of government pricing, the Conference Forum is expanding its coverage of the MRS Summit and is happy to announce that the 2015 program is newly branded as the Government Drug Pricing Forum.

The GDP Forum will cover changes in MDRP, 340B, Tricare and Medicaid Managed Care. It specifically addresses the AMP Final Rule, HRSA guidance and price reporting, rise of contract pharmacies, new state reporting requirements and government and commercial contracting rules. This event brings together CMS, FDA, IRS, HRSA, States and OIG to address how to be compliant with separate agency requirements. Attendees will walk away with a thorough overview of healthcare trends and GDP policies that drive strategic decisions and operational plans.

Featured Speakers

Lori Reilly
EVP, Policy and Research, PhRMA

Laurel Todd
Managing Director, Reimbursement and Health Policy, BIO

Don Bell
SVP and General Counsel, National Association Chain Drug Store (NACDS)

Ann Maxwell
Assistant Inspector General for Evaluations, Office of Evaluation and Inspections, Office of Inspector General

Andrew Wilson
VP, 340B Solutions, McKesson

Alice Valder Curran
Partner, Hogan Lovells

John Shakow
Partner, FDA & Life Sciences Practice Group, King & Spaulding

Key Manufacturer Voices

Kathleen Black
Government Contracts Compliance, Pfizer

George Kenny
Senior Account Manager, 340B Managed Care and Customer Operations, Genentech

Stephanie Kupski
Senior Director, Managed Markets and HCP Compliance, Iroko Pharmaceuticals

Ed McAdam
Senior Director, Payer Marketing and Contract Strategy, Daiichi Sankyo

Jay McKinley
Senior Director, Government Pricing and Commercial Operations, Dendreon

Lorraine Moccio
Director, Government Contracting and Pricing Compliance Officer, Johnson & Johnson

The GDP Forum Agenda Organized By:

  • Healthcare Trends and Policy Expectations: From ACOs and AMP to Contract Pharmacies
  • New State Reporting Requirements and Tricare Contracting
  • Drug Channel Contracting Strategies
  • Compliant Government Pricing Programs

Half Day Workshop Choices

  • Government Pricing Programs 101
  • 340B Program Policies, Operational Answers, and Audits Findings

Let us know if you have any questions and take advantage of the early bird rate.
We look forward to greeting you on February 11 in Washington DC.

Sincerely,

Anne Reel B&W

 

 

Anne Reel
Conference Director

Valerie Bowling B&W New

 

 

Valerie Bowling
Executive Director

Jessica Rothenberg B&W

 

 

Jessica Rothenberg
Marketing Director